Cargando…

422. Performance Evaluation of a Rapid and Easy-to-Use COVID-19 Test

BACKGROUND: The BioFire(®) COVID-19 Test is a qualitative test for use on the FilmArray(®) 2.0 and Torch systems for the detection of SARS-CoV-2 RNA in nasopharyngeal swabs (NPS) in transport media. This test received Emergency Use Authorization from the FDA. A closed, disposable pouch contains all...

Descripción completa

Detalles Bibliográficos
Autores principales: Toxopeus, Corike, Jones, Brian, Brown, Jessica, Gurling, Mark, Andjelic, Cynthia, Phillips, Cynthia L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777157/
http://dx.doi.org/10.1093/ofid/ofaa439.616
_version_ 1783630838064218112
author Toxopeus, Corike
Jones, Brian
Brown, Jessica
Gurling, Mark
Andjelic, Cynthia
Phillips, Cynthia L
author_facet Toxopeus, Corike
Jones, Brian
Brown, Jessica
Gurling, Mark
Andjelic, Cynthia
Phillips, Cynthia L
author_sort Toxopeus, Corike
collection PubMed
description BACKGROUND: The BioFire(®) COVID-19 Test is a qualitative test for use on the FilmArray(®) 2.0 and Torch systems for the detection of SARS-CoV-2 RNA in nasopharyngeal swabs (NPS) in transport media. This test received Emergency Use Authorization from the FDA. A closed, disposable pouch contains all the necessary reagents for sample preparation, nucleic acid extraction, reverse transcription, polymerase chain reaction (PCR), and amplified nucleic acid detection to identify RNA from SARS-CoV-2 virus in an NPS specimen. Internal controls monitor all stages of the test process. Once an NPS sample (0.3 mL) is loaded into the system disposable pouch (Figure 1), the fully automated test returns results within an hour. As an additional resource, the BioFire(®) COVID-19 Test External Control Kit (+) includes positive external control material that may be used for quality control and laboratory verification. Figure 1. BioFire COVID-19 Test Disposable Pouch [Image: see text] METHODS: The following were evaluated: • Limit of Detection (LoD) • Positive and Negative Percent Agreement (PPA and NPA, respectively) for clinical contrived samples and a limited number of clinical specimens • Exclusivity RESULTS: • LoD The LoD was evaluated using live SARS-CoV-2 virus (cultured from the USA_WA1/2020 strain obtained from World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)). The LoD was determined to be 3.3E+02 GC/mL (2.2E-02 TCID(50)/mL). • Clinical Contrived Accurate detection of virus in clinical matrix was demonstrated at various LoD levels using thirty contrived individual unique clinical samples (PPA), and 66 individual unique negative clinical specimens (NPA). • Clinical Samples Positive samples were collected from patients presenting with signs or symptoms of COVID-19, and who were previously identified as positive for SARS-CoV-2 by another EUA test. Negative samples were collected in 2018, and therefore presumed negative for SARS-CoV-2. • Exclusivity The potential for cross-reactivity was evaluated for six viruses from the same genetic family as SARS- CoV-2, and for an additional 30 high priority organisms/viruses. No cross-reactivity was observed. Table 1. SARS-CoV-2 Virus Test Results at 1× and 0.1× LoD for the BioFire COVID-19 Test [Image: see text] Table 2. Clinical Contrived and Negative Testing with the BioFire COVID-19 Test [Image: see text] Table 3. BioFire COVID-19 Test Performance Summary [Image: see text] CONCLUSION: The BioFire COVID-19 Test reliably detects SARS-CoV-2 virus RNA in clinically relevant samples. DISCLOSURES: Corike Toxopeus, PhD, BioFire Defense, LLC. (Employee, stock owner) Brian Jones, PhD., BioFire Defense, LLC (Employee, own stock) Jessica Brown, BS, BioFire Defense (Employee, Stock owner) Mark Gurling, PhD, BioFire Defense, LLC (Employee) Cynthia Andjelic, PhD., BioFire Defense (Employee, Other Financial or Material Support, Own stocks) Cynthia L. Phillips, PhD, BioFire Defense (Employee, Scientific Research Study Investigator, Shareholder)BioFire Defense (Employee, Scientific Research Study Investigator, Shareholder)
format Online
Article
Text
id pubmed-7777157
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77771572021-01-07 422. Performance Evaluation of a Rapid and Easy-to-Use COVID-19 Test Toxopeus, Corike Jones, Brian Brown, Jessica Gurling, Mark Andjelic, Cynthia Phillips, Cynthia L Open Forum Infect Dis Poster Abstracts BACKGROUND: The BioFire(®) COVID-19 Test is a qualitative test for use on the FilmArray(®) 2.0 and Torch systems for the detection of SARS-CoV-2 RNA in nasopharyngeal swabs (NPS) in transport media. This test received Emergency Use Authorization from the FDA. A closed, disposable pouch contains all the necessary reagents for sample preparation, nucleic acid extraction, reverse transcription, polymerase chain reaction (PCR), and amplified nucleic acid detection to identify RNA from SARS-CoV-2 virus in an NPS specimen. Internal controls monitor all stages of the test process. Once an NPS sample (0.3 mL) is loaded into the system disposable pouch (Figure 1), the fully automated test returns results within an hour. As an additional resource, the BioFire(®) COVID-19 Test External Control Kit (+) includes positive external control material that may be used for quality control and laboratory verification. Figure 1. BioFire COVID-19 Test Disposable Pouch [Image: see text] METHODS: The following were evaluated: • Limit of Detection (LoD) • Positive and Negative Percent Agreement (PPA and NPA, respectively) for clinical contrived samples and a limited number of clinical specimens • Exclusivity RESULTS: • LoD The LoD was evaluated using live SARS-CoV-2 virus (cultured from the USA_WA1/2020 strain obtained from World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)). The LoD was determined to be 3.3E+02 GC/mL (2.2E-02 TCID(50)/mL). • Clinical Contrived Accurate detection of virus in clinical matrix was demonstrated at various LoD levels using thirty contrived individual unique clinical samples (PPA), and 66 individual unique negative clinical specimens (NPA). • Clinical Samples Positive samples were collected from patients presenting with signs or symptoms of COVID-19, and who were previously identified as positive for SARS-CoV-2 by another EUA test. Negative samples were collected in 2018, and therefore presumed negative for SARS-CoV-2. • Exclusivity The potential for cross-reactivity was evaluated for six viruses from the same genetic family as SARS- CoV-2, and for an additional 30 high priority organisms/viruses. No cross-reactivity was observed. Table 1. SARS-CoV-2 Virus Test Results at 1× and 0.1× LoD for the BioFire COVID-19 Test [Image: see text] Table 2. Clinical Contrived and Negative Testing with the BioFire COVID-19 Test [Image: see text] Table 3. BioFire COVID-19 Test Performance Summary [Image: see text] CONCLUSION: The BioFire COVID-19 Test reliably detects SARS-CoV-2 virus RNA in clinically relevant samples. DISCLOSURES: Corike Toxopeus, PhD, BioFire Defense, LLC. (Employee, stock owner) Brian Jones, PhD., BioFire Defense, LLC (Employee, own stock) Jessica Brown, BS, BioFire Defense (Employee, Stock owner) Mark Gurling, PhD, BioFire Defense, LLC (Employee) Cynthia Andjelic, PhD., BioFire Defense (Employee, Other Financial or Material Support, Own stocks) Cynthia L. Phillips, PhD, BioFire Defense (Employee, Scientific Research Study Investigator, Shareholder)BioFire Defense (Employee, Scientific Research Study Investigator, Shareholder) Oxford University Press 2020-12-31 /pmc/articles/PMC7777157/ http://dx.doi.org/10.1093/ofid/ofaa439.616 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Toxopeus, Corike
Jones, Brian
Brown, Jessica
Gurling, Mark
Andjelic, Cynthia
Phillips, Cynthia L
422. Performance Evaluation of a Rapid and Easy-to-Use COVID-19 Test
title 422. Performance Evaluation of a Rapid and Easy-to-Use COVID-19 Test
title_full 422. Performance Evaluation of a Rapid and Easy-to-Use COVID-19 Test
title_fullStr 422. Performance Evaluation of a Rapid and Easy-to-Use COVID-19 Test
title_full_unstemmed 422. Performance Evaluation of a Rapid and Easy-to-Use COVID-19 Test
title_short 422. Performance Evaluation of a Rapid and Easy-to-Use COVID-19 Test
title_sort 422. performance evaluation of a rapid and easy-to-use covid-19 test
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777157/
http://dx.doi.org/10.1093/ofid/ofaa439.616
work_keys_str_mv AT toxopeuscorike 422performanceevaluationofarapidandeasytousecovid19test
AT jonesbrian 422performanceevaluationofarapidandeasytousecovid19test
AT brownjessica 422performanceevaluationofarapidandeasytousecovid19test
AT gurlingmark 422performanceevaluationofarapidandeasytousecovid19test
AT andjeliccynthia 422performanceevaluationofarapidandeasytousecovid19test
AT phillipscynthial 422performanceevaluationofarapidandeasytousecovid19test